| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens
|
Veal, Gareth J.
|
|
2016
|
77 |
4 |
p. 685-692
|
artikel
|
| 2 |
A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study
|
Cohen, Steven J.
|
|
2016
|
77 |
4 |
p. 693-701
|
artikel
|
| 3 |
A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers
|
Knight, Beverly
|
|
2016
|
77 |
4 |
p. 839-846
|
artikel
|
| 4 |
Celecoxib induces apoptosis but up-regulates VEGF via endoplasmic reticulum stress in human colorectal cancer in vitro and in vivo
|
Xu, Bingfei
|
|
2016
|
77 |
4 |
p. 797-806
|
artikel
|
| 5 |
Epigenetic alternations and cancer chemotherapy response
|
Lv, Jin-Feng
|
|
2015
|
77 |
4 |
p. 673-684
|
artikel
|
| 6 |
Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases
|
Fu, Siqing
|
|
2016
|
77 |
4 |
p. 881
|
artikel
|
| 7 |
Inhibition of E-selectin expression on the surface of endothelial cells inhibits hepatocellular carcinoma growth by preventing tumor angiogenesis
|
Borentain, Patrick
|
|
2016
|
77 |
4 |
p. 847-856
|
artikel
|
| 8 |
Mass balance, pharmacokinetics, and metabolism of linsitinib in cancer patients
|
Poondru, Srinivasu
|
|
2016
|
77 |
4 |
p. 829-837
|
artikel
|
| 9 |
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies
|
Planchard, David
|
|
2016
|
77 |
4 |
p. 767-776
|
artikel
|
| 10 |
Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity
|
Guenancia, Charles
|
|
2016
|
77 |
4 |
p. 777-785
|
artikel
|
| 11 |
Oxytocin as a protective agent in cisplatin-induced ototoxicity
|
Bekmez Bilmez, Zekiye Eda
|
|
2016
|
77 |
4 |
p. 875-879
|
artikel
|
| 12 |
Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors
|
Lucchesi, Maurizio
|
|
2016
|
77 |
4 |
p. 857-864
|
artikel
|
| 13 |
Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial)
|
Petty, Russell
|
|
2016
|
77 |
4 |
p. 819-827
|
artikel
|
| 14 |
Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer
|
Trafalis, Dimitrios T.
|
|
2016
|
77 |
4 |
p. 713-722
|
artikel
|
| 15 |
Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma
|
Ouellet, Daniele
|
|
2016
|
77 |
4 |
p. 807-817
|
artikel
|
| 16 |
Population pharmacokinetics and exposure–response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection
|
Gupta, Anubha
|
|
2016
|
77 |
4 |
p. 733-743
|
artikel
|
| 17 |
Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors
|
Goel, Varun
|
|
2016
|
77 |
4 |
p. 745-755
|
artikel
|
| 18 |
Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients
|
Kim, Seong-Jang
|
|
2016
|
77 |
4 |
p. 723-731
|
artikel
|
| 19 |
Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis
|
Shin, Dong-Yeop
|
|
|
77 |
4 |
p. 865-873
|
artikel
|
| 20 |
Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis
|
Shin, Dong-Yeop
|
|
2016
|
77 |
4 |
p. 865-873
|
artikel
|
| 21 |
Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors
|
Tamura, Kenji
|
|
2016
|
77 |
4 |
p. 787-795
|
artikel
|
| 22 |
The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A
|
Chen, Ya-Tian
|
|
2016
|
77 |
4 |
p. 757-765
|
artikel
|
| 23 |
Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy
|
Li, Yanli
|
|
2016
|
77 |
4 |
p. 703-712
|
artikel
|
| 24 |
Unique features of trabectedin mechanism of action
|
Larsen, Annette K.
|
|
2015
|
77 |
4 |
p. 663-671
|
artikel
|
Tijdschrift beschrijving